AI-powered Medical Imaging Platform & 3D Application Solution

https://korean-electronics.com//inquiry

 [INQ. NO. 2205E08] The medical industry is also actively adopting the new metaverse technology to areas ranging from medical education to skills training, surgery, and clinical trials. The metaverse technology is also being utilized in diverse ways to help patients identify medical facilities within hospitals and receive remote medical counseling.
Medical IP, a company specialized in AI-powered medical imaging platforms and 3D application solutions, is garnering attention as a leader in medical metaverse technology by introducing digital twin technology based on a patient’s medical data and commercializing anatomical VR, AR products.


Even before metaverse became a buzzword, Medical IP has been linking medical data with cutting-edge technology including AI, AR, and VR to materialize digital twin technology that can be utilized by many in the medical field, focusing on developing medical solutions that can maximize the usage of medical imaging while contributing to saving the lives of patients and intensifying medical practitioners’ capabilities.
Based on this, Medical IP was able to secure the necessary medical metaverse technology utilizing patients’ anatomical data in the 3D environment.
Medical IP’s metaverse solution was developed by integrating its proprietary medical imaging 3D modeling and AI segmentation technology, CAD/CAM design, and then linking patient’s digital twin data with VR, AR, XR technology.
Using its representative product, ‘MEDIP PRO,’ that has completed MFDS, FDA, CE certification, Medical IP has been enabling 3D modeling of CT, MRI, and other medical imaging data of patients as well as using intensified AI technology to swiftly and accurately divide all types of anatomical structure including organs and lesions.
Based on such source technology, Medical IP was able to process the divided human structure using its own CAD/CAM design to enhance the level of completion, and ultimately using it to materialize the metaverse technology by creating VR, AR anatomical contents.
Medical IP is now accelerating the development and commercialization of core products that can most effectively utilize medical metaverse technology based on patients’ digital twin including areas of ‘medical education,’ ‘surgical navigation,’ and ‘surgical training.’
Lately, Medical IP has completed the 5th round of advancement of its ‘MDBOX,’ a metaverse platform, and has successfully signed supply contract with medical colleges that are seeking practical anatomy education.

MDBOX is a product that has brought delicate human body information into VR space, so that users can experience a high level of practical education without the need to use a cadaver (corpse used to study anatomy). Medical IP has signed contracts for this platform and is in the process of negotiating product supply to numerous medical schools.
Hopes are also high for MEDIP PRO AR, a surgical navigation AR platform that can be used to increase surgical stability. It can allow users to decide surgical routes in an accurate and safe manner by enabling them to check human body structure created with AR technology with the naked eye.
In particular, MEDIP PRO AR recently became Korea’s first surgical guide product linked with metaverse technology to acquire certification by the Ministry of Food and Drug Safety. Likewise, Medical IP is showing remarkable achievements in the medical metaverse sector.
CEO Park Sang-joon noted, “There have been numerous attempts to integrate VR, AR, and other cutting-edge technology to create metaverse, but there are not many companies that have developed and commercialized products applicable to the actual medical environment as enhancing usefulness in medical education and surgical accuracy through utilizing digital twin technology.”
He also explained, “We will strive to become a top player in the medical metaverse sector by not only diversifying solutions to materialize patients’ medical data in the metaverse environment but also by introducing technology that can lead paradigm changes across the entire medical cycle.”


 
korean-electronics.com | Blog Magazine of korean electronics, brands and Goods

Automatic Body Composition Analysis Solution & Disease Monitoring Solution

https://korean-electronics.com//inquiry

[INQ. NO. 2106E18] MEDICAL IP Co., Ltd., specializing in medical AI total solutions, presented a precision health AI medical solution in preparation for the aging society and the era of new infectious diseases at the 36th Korea International Medical Equipment Show (KIMES 2021).
The company has unveiled its latest medical solution line-up, based on medical imaging prediction technology using AI, and is actively promoting its innovative AI technology that enables disease prevention and monitoring utilizing medical imaging data acquired from CT and X-ray.
With AI segmentation and 3D modeling of medical imaging technology and data labeling capacity, based on high-quality medical images acquired from Seoul National University Hospital and abundant anatomy knowledge from a team of experts, MEDICAL IP is further positioning itself as a strong player in the precision health AI industry.
MEDICAL IP has successfully developed numerous medical platforms – including AI medical imaging segmentation solutions, medical 3D printing simulators, medical AR and VR contents – that can be utilized practically in the medical field by continuously upgrading its technology and products.

Automatic Body Composition Analysis Solution & Disease Monitoring Solution


MEDICAL IP has also been in the spotlight lately as it has unveiled a series of innovative new products – including “DeepCatch,” automatic body composition analysis software utilizing AI and “TiSepX,” a disease quantification and monitoring solution utilizing X-ray.
MEDICAL IP was the third company within the medical imaging segmentation and modeling sector to acquire U.S. FDA approval for its flagship product, “MEDIP PRO.” It is an AI-based medical imaging segmentation software product with verified competitiveness and technology of global standard as it has received authorization by both Korea’s Ministry of Food and Drug Safety and Europe’s CE marking.
The product not only enables users to examine organs and lesions more accurately in the body by converting medical images acquired by CT and MRI into 3D modeling, but also maximizes analytic efficiency by segmenting each area in a swift and accurate way utilizing AI technology. Based on such technologies, MEDICAL IP aims to diversify its product line-up going forward by targeting numerous illnesses.

Automatic Body Composition Analysis Solution & Disease Monitoring Solution


Among these, “DeepCatch,” launched late last year to specialize in the research of cancer, obesity, sarcopenia, osteoporosis, metabolic syndrome and other illnesses of the aged, has been adopted by major university hospitals in Korea and international cancer research institutes. It is thus leading to an increase in demand within the sector of CT-based body composition research.
This is because body composition research, which is closely related to medical prognoses and fatality rates, is becoming the subject of active research in many countries around the world, especially amid an urgent need to prepare for responses against illnesses of the aged and chronic metabolic disorders due to the aging population.
CT data is uploaded, “DeepCatch” immediately analyzes body composition with 97% accuracy – including skin, bone, muscle, abdominal visceral fat, subcutaneous fat, internal organs, central nervous system – and delivers an automatic analysis report on the volume and area of muscle and fat, abdominal circumference, and body fat percentage.
This is an innovative solution that MEDICAL IP developed by applying AI medical imaging automatic segmentation technology to “body composition” to contribute to the prevention and research of metabolic disorders globally.
In addition, MEDICAL IP unveiled its AI platform “TiSepX,” which utilizes X-ray imaging that is most widely used in medical radiology to predict and quantify lung disorders, which also enables the monitoring of treatment efficacy and improvement trends.
“TiSepX” is a product that has been designed to collect 3D information on the degree of lung damage delivered from 2D X-ray utilizing AI deep learning. Last year, MEDICAL IP provided its “TiSepX COVID19,” a platform that quantifies COVID-19, free of charge to contribute to combating the pandemic, as almost all countries suffered from shortages of medical resources.

Automatic Body Composition Analysis Solution & Disease Monitoring Solution


At KIMES 2021, MEDICAL IP unveiled “TiSepX TB,” a device that not only categorizes active pulmonary tuberculosis (TB) and latent or inactive TB patients by utilizing AI-based X-ray disease prediction technology, but also identifies the TB activity index to enable the visualization of treatment efficacy.
“TiSepX TB” quantifies the area of the lung that has been damaged by pulmonary TB, enabling easy monitoring of therapeutic treatment efficacy and activity index. Compared to existing AI products that simply diagnose and identify TB infection, the product provides the world’s only solution to monitor the treatment efficacy and the disease even after full recovery by utilizing statistical data for active and inactive TB.
Therefore, it is expected to be widely used for tuberculosis patients whose treatment progress cannot be monitored easily with the naked eye.


korean-electronics.com | Blog Magazine of korean electronics, brands and Goods